2-羟基萘-3-羧酸钠盐

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-羟基萘-3-羧酸钠盐
• 英文名称: Sodium 3-hydroxynaphthalene-2-carboxylate
• 英文别名: 3-hydroxy-2-napthoic acid sodium salt；Na-2-hydroxynaphthoat-(3)；2-hydroxynaphthalene-3-carboxylic acid sodium salt；sodium 2-hydroxynaphthalene-3-carboxylate；sodium salt of 2-hydroxynaphthalene-3-carboxylic acid；3-Hydroxy-[2]naphthoesaeure; Natrium-Salz；3-hydroxy-[2]naphthoic acid ; sodium-salt；sodium 3-hydroxy-2-naphthoate；Sodium 3-carboxynaphthalen-2-olate；sodium;3-carboxynaphthalen-2-olate
• 化学式: C₁₁H₇O₃*Na
• 分子量: 210.165
• InChiKey: ZCNGWQCRXUGQCW-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.38
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙咪嗪 、 2-羟基萘-3-羧酸钠盐 以 水 为溶剂， 反应 20.0h， 以12.7 g的产率得到imipramine xinafoate
  参考文献：
  名称：

  SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS

  摘要：

  含有胺基药用活性化合物的药物物质，以及至少一种醛糖醚和芳香有机酸中的一种作为附加盐或添加剂。

  公开号：

  US20140178480A1
• 作为产物：
  描述：

  2-羟基-3-萘甲酸 在 sodium hydroxide 作用下， 以 甲苯 为溶剂， 生成 2-羟基萘-3-羧酸钠盐
  参考文献：
  名称：

  Process for the preparation of pure, aromatic o-hydroxy-carboxylic acid

  摘要：

  制备纯芳香族o-羟基-羧酸芳基酰胺的方法是，在有机溶剂或稀释剂中存在磷氯化物的情况下，通过将芳香族o-羟基-羧酸与芳基胺缩合反应，该过程包括用1至25％（按反应产物重量计算）的脂肪族氨基聚羧酸作为螯合剂处理反应混合物或反应产物。不需要纯化产物，因为它们以如此纯净的形式获得，可以直接用作偶氮颜料的耦合组分。

  公开号：

  US03947515A1

文献信息

• Crystal of 2-hydroxynaphthalene-3-carboxylic acid and process for the preparation thereof
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo K.

  公开号：US06403827B1

  公开（公告）日：2002-06-11

  The present invention provides crystalline 2-hydroxynaphthalene-3-carboxylic acid (BON) characterized in that the average particle size is equal to or more than 157 &mgr;m and the proportion of the particles of which particle size is less than 74 &mgr;m is equal to or less than 14%. The crystalline composition of the present invention can be prepared by a process comprising the step of recrystallizing BON, especially at a high temperature, or by carrying out the acid precipitation step in the method for preparing BON at a high temperature.

  本发明提供了结晶的2-羟基萘-3-羧酸（BON），其平均粒径等于或大于157μm，并且粒径小于74μm的颗粒比例等于或小于14％。本发明的晶体组合物可以通过再结晶BON的步骤，特别是在高温下，或通过在制备BON的方法中进行酸沉淀步骤来制备。
• An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0036534A1

  公开（公告）日：1981-09-30

  A drug form is provided for increasing the oral absorption of β-lactam antibiotics such as the penicillins, cephalosporins and related chemical species by the oral administration of said β-lactam antibiotics in a suitable pharmaceutically accepted excipient to which has been added a hydroxy aryl or hydroxy aralkyl acid or salt, amide or ester thereof. The hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of the β-lactam antibiotic.

  本发明提供了一种药物形式，通过将β-内酰胺类抗生素口服于适当的药学上可接受的赋形剂中，并在赋形剂中加入羟基芳基或羟基芳烷基酸或其盐、酰胺或酯，从而增加β-内酰胺类抗生素如青霉素类、头孢菌素类及相关化学物质的口服吸收。羟基芳基或羟基烷基酸或其盐、酰胺或酯在药物形式中的含量足以有效提高 β-内酰胺类抗生素的口服吸收率。
• An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0035770A2

  公开（公告）日：1981-09-16

  A drug form is provided for increasing the oral absorption of glycosidic and related antibiotics such as marcrolide, aminoglycoside, lincomycin and anthracycline antibiotics and related chemical species by the oral administration of said glycosidic and related antibiotics in a suitable pharmaceutically accepted excipient to which has been added a hydroxyaryl or hydroxyaralkyl acid or salt amide or ester thereof. The hydroxyaryl, a hydroxyaralkyl or salt amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of glycosidic and related antibiotic.

  本发明提供了一种药物剂型，用于提高糖苷类和相关抗生素（如马克隆、氨基糖苷、林可霉素和蒽环类抗生素及相关化学物质）的口服吸收率，方法是将所述糖苷类和相关抗生素置于适当的药学上可接受的赋形剂中，并在赋形剂中添加羟基芳基或羟基烷基酸或盐酰胺或酯。 药物剂型中羟基芳基、羟基烷基或盐酰胺或酯的含量足以有效提高糖苷类和相关抗生素的口服吸收率。
• An orally administered drug form comprising a polar bioactive agent and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0036145A1

  公开（公告）日：1981-09-23

  A drug form is provided for increasing the oral absorption of polar bioactive agents such as xanthines, polyhydroxylic substances, zwitterions, polypeptides and organic anions and related chemical species by the oral administration of said polar bioactive agents in a suitable pharmaceutically accepted excipientto which has been added a hydroxyaromatic, hydroxyaryl or hydroxy aralkyl acid or salt amide or ester thereof. The hydroxy aryl or hydroxy aralkyl acid or salt amide or ester thereof is present in the drug form in quantities suffi- cientto be effective in enhancing the rate of oral absorption of the polar bioactive agents.

  本发明提供了一种药物剂型，用于增加极性生物活性剂（如黄嘌呤、多羟基物质、 齐聚物、多肽和有机阴离子及相关化学物质）的口服吸收，方法是将所述极性生物活性 剂口服在一种适当的药学上可接受的赋形剂中，在赋形剂中添加羟基芳基、羟基芳基或 羟基烷基酸或其酰胺盐或酯。羟基芳基或羟基烷基酸或其酰胺盐或酯在药物形式中的存在量足以有效提高极性生物活性剂的口服吸收率。
• Depostion processes
  申请人：Albright & Wilson Limited

  公开号：EP0162640A1

  公开（公告）日：1985-11-27

  Water insoluble resin additives are incorporated into electrophoretic resin films by immersing the uncured resin film after deposition but before curing in a solution of the additive in solvent medium comprising water and a water miscible organic solvent. The composition of the solvent medium is controlled so as to ensure that the additive is absorbed into the film without damage to the integrity of the film. In a preferred embodiment the solvent medium comprises a hydrotrope which enables the proportion of solvent in the reaction medium to be reduced.

  水不溶树脂添加剂可通过以下方法加入到电泳树脂薄膜中：在沉积后但在固化前，将未固化的树脂薄膜浸入由水和水混溶有机溶剂组成的溶剂介质中的添加剂溶液中。 溶剂介质的成分应加以控制，以确保添加剂被吸收到薄膜中，而不会破坏薄膜的完整性。 在一个优选的实施方案中，溶剂介质包括一种水溶胶，它可以降低反应介质中溶剂的比例。

表征谱图